Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Sells $400,300.00 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $40.03, for a total value of $400,300.00. Following the completion of the transaction, the chief financial officer now directly owns 101,959 shares in the company, valued at $4,081,418.77. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jack Anders also recently made the following trade(s):

• On Monday, March 18th, Jack Anders sold 1,261 shares of Revolution Medicines stock. The stock was sold at an average price of $31.58, for a total value of $39,822.38.

Revolution Medicines Stock Up 2.6 %

NASDAQ RVMD opened at $40.20 on Monday. Revolution Medicines, Inc. has a twelve month low of $15.44 and a twelve month high of $40.21. The firm has a market capitalization of $6.85 billion, a PE ratio of -10.66 and a beta of 1.46. The stock’s 50 day moving average is $33.25 and its 200 day moving average is $28.30.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Monday, February 26th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.29). The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $1.20 million. During the same quarter in the previous year, the company earned ($0.63) EPS. The firm’s quarterly revenue was down 95.2% compared to the same quarter last year. On average, research analysts anticipate that Revolution Medicines, Inc. will post -3.18 earnings per share for the current year.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently added to or reduced their stakes in RVMD. Handelsbanken Fonder AB boosted its holdings in Revolution Medicines by 6.0% in the third quarter. Handelsbanken Fonder AB now owns 14,200 shares of the company’s stock worth $393,000 after acquiring an additional 800 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Revolution Medicines by 2.1% in the third quarter. Bank of New York Mellon Corp now owns 420,366 shares of the company’s stock worth $11,636,000 after acquiring an additional 8,825 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Revolution Medicines by 15.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,685 shares of the company’s stock worth $462,000 after acquiring an additional 2,199 shares in the last quarter. Strs Ohio boosted its holdings in Revolution Medicines by 270.6% in the third quarter. Strs Ohio now owns 6,300 shares of the company’s stock worth $174,000 after acquiring an additional 4,600 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in Revolution Medicines by 106.2% in the third quarter. TD Asset Management Inc now owns 271,824 shares of the company’s stock worth $7,524,000 after acquiring an additional 140,012 shares in the last quarter. 94.34% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on RVMD. Raymond James raised Revolution Medicines from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $36.00 to $48.00 in a research note on Wednesday, April 10th. Piper Sandler began coverage on Revolution Medicines in a research note on Monday, March 11th. They set an “overweight” rating and a $43.00 target price on the stock. Wedbush boosted their target price on Revolution Medicines from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Oppenheimer boosted their target price on Revolution Medicines from $43.00 to $45.00 and gave the company an “outperform” rating in a research note on Friday, April 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $46.00 target price (up from $36.00) on shares of Revolution Medicines in a research note on Monday, April 8th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $41.20.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.